Founded in 1993 in San Francisco, Biotechnology Value Fund invests in early stage ventures, post-IPO equity, series B, series C, grants, and post-IPO debt. It has made 31 investments, with notable portfolio companies including Kymera Therapeutics, Syndax Pharmaceuticals, Pieris Pharmaceuticals, and Revolution Medicines. The fund has had 20 exits, with the most notable ones being Evotec, Blueprint Medicines, and IDEAYA Biosciences. Biotechnology Value Fund has raised a single venture fund, Biotechnology Value Fund II, and is committed to working closely with its portfolio companies as partners in their successes.